A feasibility study of capecitabine and oxaliplatin (XELOX) for patients with stage II/III colon cancer.
Phase 2
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000008029
- Lead Sponsor
- Japanese Foundation for Cancer Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
1. Severe peripheral sensory neuropathy 2. History of the serious hypersensitivity for drugs. 3. Active infection. 4. Complications (Evidence of interstinal lung disease, or pulmonary fibrosis, paralytic or mechanical bowel obstruction, uncontrolled hypertension, uncontrolled diabetes mellitus, cirrhosis, active cardiovascular disease, or past or current history (within 3 months) of myocardial infarction. 5. Multiple primary cancer within 5years. 6. Uncontrolled diarrhea. 7. Clinically significant mental or psychological disease. 8. Pregnancy, lactation period. 9. Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Completion rate of treatment
- Secondary Outcome Measures
Name Time Method 1 Completion rate of L-OHP 2 Disease-free survival 3 Recurrent-free survival 4 Overall survival 5 Adverse effect 6 Correlation of relative dose intensity with prognosis 7 Correlation of stage with prognosis